RGEN icon

Repligen

122.85 USD
-2.45
1.96%
At close Jul 30, 4:00 PM EDT
After hours
122.85
+0.00
0.00%
1 day
-1.96%
5 days
5.59%
1 month
-1.23%
3 months
-10.97%
6 months
-26.67%
Year to date
-14.12%
1 year
-23.50%
5 years
-18.78%
10 years
251.20%
 

About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Employees: 1,778

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

38% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 45

29% more repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 130

2% more funds holding

Funds holding: 429 [Q4 2024] → 439 (+10) [Q1 2025]

1.43% more ownership

Funds ownership: 100.37% [Q4 2024] → 101.8% (+1.43%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

10% less capital invested

Capital invested by funds: $8.09B [Q4 2024] → $7.31B (-$782M) [Q1 2025]

84% less call options, than puts

Call options by funds: $11M | Put options by funds: $68.6M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$130
6%
upside
Avg. target
$167
36%
upside
High target
$204
66%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
RBC Capital
Conor McNamara
66%upside
$204
Outperform
Maintained
30 Jul 2025
Wells Fargo
Brandon Couillard
42%upside
$175
Overweight
Maintained
30 Jul 2025
Stephens & Co.
Steven Etoch
30%upside
$160
Overweight
Assumed
22 Jul 2025
Evercore ISI Group
Daniel Markowitz
6%upside
$130
In-Line
Maintained
8 Jul 2025
Barclays
Luke Sergott
22%upside
$150
Overweight
Initiated
24 Jun 2025

Financial journalist opinion

Based on 5 articles about RGEN published over the past 30 days

Neutral
Seeking Alpha
1 day ago
Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Officer Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Justin D.
Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 day ago
Repligen (RGEN) Lags Q2 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.
Repligen (RGEN) Lags Q2 Earnings Estimates
Neutral
GlobeNewsWire
1 day ago
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today's webcast and conference call.
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Positive
Zacks Investment Research
1 week ago
Here's Why Repligen (RGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Repligen (RGEN) is a Strong Growth Stock
Neutral
GlobeNewsWire
1 week ago
Repligen to Report Second Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET
Repligen to Report Second Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
908 Devices Appoints Christopher D. Brown to its Board of Directors
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2.
908 Devices Appoints Christopher D. Brown to its Board of Directors
Negative
Zacks Investment Research
2 months ago
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Neutral
GlobeNewsWire
2 months ago
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two key reporting frameworks: the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB), now part of the IFRS Sustainability Alliance.
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report
Neutral
GlobeNewsWire
2 months ago
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
Repligen Corporation to Present at Upcoming May Investor Conferences
Positive
Zacks Investment Research
2 months ago
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Charts implemented using Lightweight Charts™